[Edaily Reporter Kwon Oh Seok ] Meritz Securities announced on the 29th that it is maintaining its “Buy” rating on BNK Financial Group Inc.(138930)but lowering its target price from 26,000 won to 24,000 won. Jo Ah-hae, an analyst at Meritz Securities, explained, “Second-quarter earnings were weak,” but added, “The CET-1 (Common Equity Tier 1) ratio, which forms the foundation of the shareholder return policy, is being maintained stably within the target range of 12.0–12.5% despite asset growth.” She added, “Based on this, expectations for an aggressive shareholder return policy remain valid,” noting, “We expect the bank to meet the criteria for high-dividend companies eligible for separate taxation of dividend income this year, as it did last year, and anticipate a 50 billion won share buyback during the second half of the year.” Previously, second-quarter net income attributable to controlling shareholders came in at 200.4 billion won (down 35.2% year-over-year), falling 20% short of the consensus estimate. Analyst Cho pointed out, “This was due to a larger-than-expected decline in the NIM (net interest margin) and one-time interest expenses of 44.0 billion won incurred from the acquisition of external stakes in real estate funds.” Specifically, interest income rose by only 2.2% year-over-year due to the one-time interest expense. A settlement loss of 44 billion won resulting from the acquisition of shares in the BNK Yeouido Core Office Fund was recorded as an interest expense. Non-interest income increased by 59.8% year-over-year. This was driven not only by higher gains on the sale of loan receivables but also by expanded commission income, primarily from the subsidiary securities firm, amid a favorable stock market environment. Researcher Cho added, “The CET-1 ratio stood at 12.14%. It showed a downward trend due to an increase in RWA (risk-weighted assets) resulting from the growth in loan assets.”
The slump in the non-investment-grade corporate bond market—which has been centered on BBB-rated bonds this year—is expected to spread to A-rated companies next year. As the burden of issuing corporat…
Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor…
A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…